Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From PAVmed Inc.
PAVmed Plans Spin-Off And Marketing Push For Lucid Diagnostics
Lucid, which markets the EsoGuard test for Barrett’s esophagus, will become a separate public company, either through an IPO or a business combination with a health care SPAC.
Starts & Stops: Boston Scientific Launches New Lotus TAVR Trial, Medtronic Starts Study Of SynchroMed II Pain Pump
Starts & Stops compiles all the clinical trial announcements, initiations, completions and suspensions tracked by MedDeviceTracker. This edition covers trial announcements from Jan. 7 through Jan. 27, including announcements from Medtronic, QT Vascular, Boston Scientific, and Shockwave.
FDA Wants Resubmission On PAVmed Carpal Tunnel Syndrome 510(k)
Device manufacturer PAVmed is planning to resubmit a 510(k) for its CarpX product to treat carpal tunnel syndrome after US FDA said it couldn’t reach a consensus on approval.
Tech Transfer Roundup: Amgen Teams With MD Anderson To Accelerate Early-Stage Cancer Candidates
In a busy month, MD Anderson also partners with Ipsen on an unspecified cancer drug and licenses poziotinib IP to Spectrum. Using IP from UCLA, Bloom launches with focus on neuroprotective epilepsy therapies.
- Implantable Devices
- Surgical Equipment & Devices
- Other Names / Subsidiaries
- CapNostics, LLC.
- Lucid Diagnostics Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.